| Dear Voornaam
Our Centre for Drug Development will work together with global biopharmaceutical company UCB to bring two of its antibody candidates to the clinic. One is a first-in-class antibody, targeting the tumour stromal glycoprotein, gremlin-1, while the second targets the HLA-G immune checkpoint protein.
The Centre for Drug Development will lead the design, preparation, sponsorship and delivery of Phase 1/2 clinical trials for both drug candidates. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
NEW RESEARCH EVENTS FOR CHILDREN'S AND YOUNG PEOPLE'S CANCER Throughout 2023 we're holding events for researchers working in children's and young people's cancers and those interested in learning how they could apply their research to this area.
We're hosting a series of webinars to delve into some key topics that will provide opportunities to drive progress for children's and young people's cancer research the developmental origins of cancers, precision medicine and immunotherapy. In November, we'll bring the whole community together for a conference, with scope for networking, collaboration and debate.
The first webinar in the series is on understanding the developmental origins of cancer and how this could improve prevention and detection and lead to new treatment options for children and young people with cancer. Join us on 26 April 45.30pm BST. |
|
|---|
|
|---|
|
|
 A CAREER FORGED IN TEAM SCIENCE From early dreams of being an astronaut to a ground-breaking cancer genomics study, Mariam Jamal-Hanjani shares some of the biggest milestones of her research journey.
During a scientific career embedded in ambitious projects, Mariam has shouldered challenges in clonal evolution, metastasis and cachexia. She is now a group leader at the University College London Cancer Institute.
Find out what its like working in highly collaborative, large-scale projects like TRACERx and Cancer Grand Challenges. |
|
|---|
|  NOTHING ABOUT US WITHOUT US: OUR COMMITMENT TO PUBLIC INVOLVEMENT One year ago, we signed a new Shared Commitment to improve public involvement in health and social care research by working in partnership with other leading health organisations.
We spoke with our Patient Involvement Network members Ally Boyle and Terry Kavanagh to reflect on our successes in involving people affected by cancer in research, and on how we could do better. |
|
|---|
|
|---|
|
|
PROMISING CLINICAL RESULTS FOR HER3 ANTIBODY CANDIDATE PROMPT EARLY OPTION Impressed by the promising early clinical result in our ongoing Phase 1a trial for the potent Human Epidermal Growth Factor or HER3 receptor inhibitor, Hummingbird Bioscience moved to in-license the best-in-class antibody candidates data prior to the trials completion. The decision signals Hummingbird Bios confidence in the results and acknowledges the urgent need to bring innovative treatments to patients in need.
Participants in the trial include patients with advanced HER3-positive solid tumours. The company plans to launch multiple trials for biomarker-selected populations later this year. |
|
|---|
|
|---|
|
|
 PAUL NURSE ON RESEARCH, DEVELOPMENT AND INNOVATION IN THE UK Sir Paul Nurse, Director and Chief Executive of the Francis Crick Institute, has published an independent review of the research, development and innovation organisational landscape within the UK.
The report highlights the importance of the science ecosystem for the UK economy and the critical role that charities, institutes, and international collaboration play in its success. |
|
|---|
|  ARE YOU ATTENDING AACR 2023? With just over four weeks to go, were gearing up for the AACR annual meeting in Orlando. Were looking forward to meeting many of you there come find us at stand 2024 in the main exhibition space for a chat.
On Monday 17 April well be hosting a drinks reception for the Cancer Research UK research community. Look out for our RSVP form coming out next week.
If you're presenting a poster or speaking at the conference, let us know and we'll give you a shout out on our social accounts. |
|
|---|
|
|---|
|
|
TOP TEAMS PROGRESS TO PHASE 2 OF CANCER TECH ACCELERATOR From an AI-driven approach to predict the effects of therapeutics in patients to the development of a medical device targeting the most common malignant brain tumour in adults, participants in the Cancer Tech Accelerator take on some of the biggest challenges in cancer using data, AI or MedTech platforms.
Created through a partnership between our innovation engine, Cancer Research Horizons, Capital Enterprise, The Medical Research Council and Roche UK, the Cancer Tech Accelerator assists cancer researchers developing these early-stage technologies.
Find out more about the top six cancer teams progressing to phase 2 of the programme. The finalists will receive 70,000 each in grant funding to progress their cutting-edge cancer research, plus an additional six months of support from the accelerator. |
|
|---|
|
|---|
|
|
 OUR #RADCONF23 PROGRAMME COMMITTEE The agenda of our Radiation Research Conference is taking form meet the stellar committee working behind the scenes to select the topics and speakers for our event: - Anthony Chalmers, School of Cancer Science, University of Glasgow
- Charlotte Coles, Department of Oncology, University of Cambridge
- Kevin Harrington, Division of Radiotherapy and Imaging, Institute of Cancer Research
- Karen Kirkby, Division of Cancer Science, University of Manchester
- Jason Parsons, Institute of Cancer and Genomic Sciences, University of Birmingham
- Chris Talbot, University of Leicester
If youd like the opportunity to showcase your work as part of the programme in our Future Leaders session, submit your abstract by 31 March. |
|
|---|
|  DEVELOP YOUR TECHNOLOGY-FOCUSED CANCER INNOVATION Across the span of 12 weeks, the University of Cambridges IMPULSE programme allows you to network and build one-on-one relationships with over 120 mentors, investors and experienced entrepreneurs to boost your tech innovation.
Since 2017, programme alumni have raised over 134m in funding and investments from business angels, venture capitalists and grant funding. Apply by 19 March for the opportunity to join.
|
|
|---|
|
|---|
|
|
| | | Online 2:00 PM 21 March 2023 |
|
|---|
|
|---|
| | | Online 4:00 PM 26 April 2023 |
|
|---|
|
|---|
| | | Glasgow, UK 27 April 2023 |
|
|---|
|
|---|
| | | Torino, Italy 12 June 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
